UPDATE: Canaccord Assumes Coverage on Optimer Pharmaceuticals

In a report published on Thursday, Canaccord assumed coverage on Optimer Pharmaceuticals

with a Buy rating and a $21 price target. In the report Canaccord stated, “Assuming coverage with BUY rating, $21 target on expectation of steady revenue growth driven by unmet need and Dificid's superior efficacy in Clostridium difficile- efficacy in Clostridium difficile---associated diarrhea (CDAD). We feel there is still unmet need given the relapse rates associated with other therapies, the rising incidence of CDAD, and the growing severity of the disease. Further, we think the pharmaco-economics of Dificid treatment will drive uptake over time, despite premium pricing. Our $21 target is based on a DCF of Dificid/Dificlir sales and royalties.” Optimer closed at $15.03 on Wednesday.